Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
- DOI
- 10.1111/1759-7714.70131
- Published
- 2025 Jul
- Container
- Thoracic cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/1759-7714.70131,
title = {Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.},
author = {Zhao W and Zhao N and Cao D},
year = {2025},
journal = {Thoracic cancer},
doi = {10.1111/1759-7714.70131},
url = {https://doi.org/10.1111/1759-7714.70131}
}RIS
TY - JOUR TI - Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study. AU - Zhao W AU - Zhao N AU - Cao D PY - 2025 JO - Thoracic cancer DO - 10.1111/1759-7714.70131 UR - https://doi.org/10.1111/1759-7714.70131 ER -
APA
W, Z., N, Z., & D, C. (2025). Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.. Thoracic cancer. https://doi.org/10.1111/1759-7714.70131
Source records
- pubmed · retrieved 2026-09-25T12:11:46.412Z